secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001493152-22-030374
Event type: other_material
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona raises $35M in private placement; Phase 3 EB-101 trial meets endpoints
-----------------------------------------------------------------------------

- Gross proceeds of $35M from sale of 7.07M shares, pre-funded warrants for 0.54M shares, and common warrants for 7.61M shares.
- Offering price per unit $4.60; common warrants exercisable at $4.75 per share for five years.
- Phase 3 VIITAL trial for EB-101 met co-primary, secondary, and exploratory endpoints with high statistical significance.
- Net proceeds plus existing resources expected to fund operations into Q3 2024.
- Placement includes new and existing investors: Adage Capital, Armistice Capital, Deerfield, EcoR1, Nantahala.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315222030374/0001493152-22-030374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315222030374/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-030374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer